JPRN-jRCT1080223924招募中Unknown
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and bulbar muscular atrophy (SBMA)
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 300 人开始时间: 2018年6月1日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All SBMA patients who have been confirmed as receiving the drug
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"Spinal and Bulbar Muscular AtrophyNCT03555578Takeda1,905
进行中（未招募）
不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - Leuprolide 3.75 mgprostate cancerEUCTR2005-002880-98-DEGP-Pharm s.a.160
进行中（未招募）
不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - Leuprolide 3.75 mgMedDRA version: 6.0Level: LLTClassification code 10007113prostate cancerEUCTR2005-002880-98-HUGP-Pharm s.a.120
进行中（未招募）
不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patientsMedDRA version: 14.1Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancerEUCTR2005-002880-98-ESGP-Pharm s.a120
进行中（未招募）
不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - Leuprolide 3.75 mgMedDRA version: 6.0Level: LLTClassification code 10007113prostate cancerEUCTR2005-002880-98-ATGP-Pharm s.a.120